Patterns of drug abuse are constantly changing. This is particularly the case regarding new psychoactive substances or designer drugs, in which new variants are continually emerging with uptake especially among young adults. New synthetic designer drugs can be challenging to identify and treat effectively, especially serious medical and psychiatric complications. This is important for practitioners, as new designer drugs have resulted in multiple deaths, as well as other significant health consequences to users. This session will educate practitioners about several newer designer drugs regarding use trends along with psychotropic and health effects.
This focus session will inform attendees with a discussion—including clinical case examples—that will focus on emerging designer drugs, including phenibut, synthetic opioids, and others. Use of these drugs has caused significant medical and psychiatric consequences, including multiple deaths, which has received recent media attention. The presentation will be evidence-based and draw from existing medical literature, and will also include the panelists’ clinical experience with patients experiencing designer drug use and complications. The emphasis will be on clinical issues, especially recognition of intoxication, problems related to detection with urine drug testing, and treatment of medical and psychiatric complications. Attention will be given to specific populations that have been shown to be using these designer drugs. The presenters are experienced clinicians who have been involved in evaluation of patients using designer drugs. The presenters have also published about designer drugs in peer-reviewed journals. Attendees will be able to share their own experiences with patient use of designer drugs to enrich the discussion. Time will be allowed for questions to the panelists so that there will be significant interaction during this focus session.
This focus session will provide attendees with evidence-based clinical knowledge to help identify and treat complications from newer designer drug use, especially those with life-threatening complications.